Peptides DB
Research-centric peptide and protocol reference hub
Study 11 of 16Vipivotide literatureExpert opinion on drug safety · Observational2025

Postmarketing safety of [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting system.

This study highlights the importance of monitoring adverse events associated with [177Lu]Lu-PSMA-617, particularly in older patients who may be at higher risk.

Read at Expert opinion on drug safetyAdd to compare

Where it sits

this study against the rest of the vipivotide corpus
3
Preclinical
10
Observational · this one
0
Open-label
2
Randomised
1
Reviews

Summary and findings

This study analyzed adverse event reports associated with [177Lu]Lu-PSMA-617 in prostate cancer patients. A total of 870 adverse events were identified from 384,2712 reports, with known and novel adverse events documented. The median onset time for these events was 55 days.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
870 adverse event reports associated with [177Lu]Lu-PSMA-617 in prostate cancer patients.n=8702025

Abstract

The authors’ words, as Expert opinion on drug safety supplied them

<h4>Background</h4>[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto), a new radioligand therapy that targets prostate-specific membrane antigen (PSMA), has been approved to treat metastatic castration-resistant prostate cancer (mCRPC). However, the real-world safety profile of [<sup>177</sup>Lu]Lu-PSMA-617 has not been systemically evaluated.<h4>Research design and methods</h4>Adverse event reports for [<sup>177</sup>Lu]Lu-PSMA-617 were retrieved from April 2022 to June 2024 from The Food and Drug Administration Adverse Event Reporting System (FAERS) database. Disproportionality analysis was conducted by four algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS) and Bayesian Confidence Propagation Neural Network (BCPNN). Subgroup analysis, time-to-onset and sensitivity analysis were also employed.<h4>Results</h4>384,2712 adverse event reports were retrieved, of which 870 were associated with [<sup>177</sup>Lu]Lu-PSMA-617 in prostate cancer patients. We identified known adverse events (fatigue/asthenia, anemia, thrombocytopenia and nausea) and discovered adverse events not specified on the label (loss of libido, hydronephrosis, supraventricular tachycardia, tumor lysis syndrome, and tumor flare). Subgroup analysis revealed high-risk signals included stomatitis, pneumonia, leukopenia, and sepsis for patients aged over 85. The median onset time was 55 days (interquartile range 24-124 days).<h4>Conclusions</h4>The findings provide new insights into the adverse events of [<sup>177</sup>Lu]Lu-PSMA-617 and valuable references for clinical applications of radioligand therapy for mCRPC.

Background

This paper addresses the safety profile of [177Lu]Lu-PSMA-617, a radioligand therapy approved for metastatic castration-resistant prostate cancer (mCRPC). Prior to this study, the real-world safety of this treatment had not been systematically evaluated, making this analysis significant for understanding potential risks associated with its use.

Methods

Adverse event reports were retrieved from the FDA Adverse Event Reporting System (FAERS) database from April 2022 to June 2024. A total of 384,2712 reports were analyzed, with 870 specifically associated with [177Lu]Lu-PSMA-617. Disproportionality analysis was conducted using four algorithms, and subgroup analyses were performed.

Results

870 adverse events were identified in patients treated with [177Lu]Lu-PSMA-617. Known adverse events included fatigue/asthenia, anemia, thrombocytopenia, and nausea, while novel events included loss of libido and tumor lysis syndrome. The median onset time for adverse events was 55 days (interquartile range 24-124 days).

Interpretation

The findings indicate both known and novel adverse events associated with [177Lu]Lu-PSMA-617, contributing to the understanding of its safety profile. While the statistical significance of the findings is noted, the clinical significance may vary, particularly in older patients. The reliance on adverse event reporting introduces potential confounds such as underreporting or bias.

Key findings

  • 870 adverse event reports associated with [177Lu]Lu-PSMA-617 in prostate cancer patients.
  • Median onset time was 55 days (interquartile range 24-124 days).
  • High-risk signals included stomatitis, pneumonia, leukopenia, and sepsis for patients aged over 85.

Limitations

  • Relies on adverse event reporting, which may be subject to underreporting.
  • Analysis based on data from the FAERS database, which may not represent the entire patient population.
  • Potential bias in reporting may affect the findings.

Elsewhere in the Vipivotide corpus

BThrombotic Microangiopathy in Patients Treated with &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA Combination Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 · n=766 · Cumulative renal absorbed dose ranged from 38.6 to 65.3 Gy.HumanDGuideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026 · 7.4 GBq every 6 weeks for up to six cycles.reviewCIdentification and functional verification of resistance genes against Lily bulb virus-1 (LbV-1) in Lilium: Insight from sRNA sequencing and transcriptomic profiling.Plant science : an international journal of experimental plant biology · 2026 · Infection rate of up to 45% in progeny plants.In vitroDClinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective.Journal of medical economics · 2026 · 66% PSA response for Lu-PSMA vs 37% for cabazitaxel, p<0.0001.reviewBTreatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC).Clinical genitourinary cancer · 2026 · n=743 · Median overall survival was 8.0 months (95% CI: 6.8-11.5).HumanDPlitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.Science (New York, N.Y.) · 2021